# A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes

> **NCT05996380** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 52 (estimated)

## Conditions studied

- T2DM

## Interventions

- **DRUG:** SHR-3167
- **DRUG:** SHR-3167 Placebo

## Key facts

- **NCT ID:** NCT05996380
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-09
- **Primary completion:** 2024-01-25
- **Final completion:** 2024-04-28
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2023-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05996380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05996380, "A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05996380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*